Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: vitamin D3 analogues - BioXell/Galapagos

Drug Profile

Research programme: vitamin D3 analogues - BioXell/Galapagos

Alternative Names: BXL 055; BXL 082; BXL 083; BXL 093

Latest Information Update: 27 May 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioXell SpA; Galapagos NV
  • Class Cholestenes; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hyperparathyroidism; Osteoporosis

Most Recent Events

  • 25 Jul 2007 Preclinical development is ongoing
  • 22 Sep 2004 ProSkelia has merged with Strakan to form ProStrakan
  • 01 Apr 2004 Preclinical trials in Hyperparathyroidism in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top